GlassScriptPhysician profile
Garo Garibian
NPI 1215909247
$114,958.33
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $22K · 2021: $26K · 2022: $27K · 2023: $9,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,300 · Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,300.00 |
| Food and Beverage | $2,550.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47,362.27 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $21,855.06 | 2020-2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $20,792.08 | 2019-2023 | Farxiga, Brilinta |
| Boston Scientific Corporation | $15,970.47 | 2019-2023 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $1,582.32 | 2021-2023 | Optimizer |
| Amgen INC. | $1,406.03 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $928.01 | 2019-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $764.02 | 2019-2023 | |
| Daiichi Sankyo INC. | $749.42 | 2019-2022 | |
| Amarin Pharma, INC. | $613.66 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.17 | 2019-2023 | Lifevest |
| W. L. Gore & Associates, INC. | $350.00 | 2019 | |
| Medtronic Vascular, INC. | $333.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.84 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $243.48 | 2021-2023 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.25 | 2019-2023 | |
| Akcea Therapeutics, INC. | $164.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $145.28 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.29 | 2021-2022 | |
| Abbott Laboratories | $143.29 | 2019-2021 | |
| Lundbeck LLC | $122.50 | 2019 | |
| Janssen Scientific Affairs, LLC | $118.82 | 2019 | |
| Althera Pharmaceuticals LLC | $43.60 | 2021 | |
| Biosense Webster, INC. | $43.43 | 2021 | |
| Novo Nordisk INC | $36.53 | 2023 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $33.32 | 2020 | |
| Medtronic, INC. | $29.35 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Irhythm Technologies, INC. | $21.48 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $20.97 | 2023 | Arcalyst |
| Preventice Services, LLC | $20.34 | 2019 | |
| Medicomp INC | $19.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garo Garibian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.